Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers

Celine Ollier, Ulrike Sent, Margarida Mesquita, Martin C Michel, Celine Ollier, Ulrike Sent, Margarida Mesquita, Martin C Michel

Abstract

Introduction: Ambroxol is used in the treatment of acute and chronic respiratory conditions characterized by abnormal mucus secretion and impaired mucus transport and is available in a variety of formulations. This study aimed to compare the steady-state (SS) pharmacokinetic characteristics of extended-release (ER) 75-mg retard capsules with two immediate-release (IR) formulations (60-mg effervescent tablets and 30-mg tablets) over a 24-h period.

Methods: An open-label, randomized, three-period, six-sequence crossover study was conducted in healthy volunteers aged 18-45 years who had a normal body mass index. The test (ER 75-mg retard capsule once daily) and reference treatments (half of IR 60-mg effervescent tablet twice daily or 30-mg IR tablet twice daily) were administered on days 1-5 of each treatment period. Meals were standardized and concomitant therapy was prohibited. Blood samples for pharmacokinetic assessment were collected on day 5 (SS) of each treatment period. The co-primary endpoints were exposure (AUCSS 0-24) and maximum plasma level (Cmax SS).

Results: Twenty-four participants received ambroxol (male n = 13, 54.2%; mean ± standard deviation [SD] age 25.0 ± 6.4 years) and 23 completed the study. ER retard capsules provided similar AUCSS 0-24 compared to IR tablets (geometric means ratio [GMR] 110.7%; 90% confidence interval [CI] 99.8%, 122.7%) and effervescent tablets (GMR 106.9%; 90% CI 100.3%, 114.0%). ER retard capsules provided similar Cmax SS compared to IR tablets (GMR 84.7%, 90% CI 77.0%, 93.3%), and lower Cmax SS compared to effervescent tablets (GMR 80.9%, 90% CI 73.9%, 88.6%). Time to Cmax SS (tmax SS) was longer with ER retard capsules (6.0 h) than with IR tablets (2.0 h) or effervescent tablets (1.0 h).

Conclusions: ER ambroxol 75-mg retard capsules given once daily showed a similar pharmacokinetic profile to IR ambroxol formulations and therefore can be used instead of these in the treatment of respiratory conditions. CLINICALTRIALS.

Gov identifier: NCT02036775.

Keywords: Ambroxol; Extended release; Immediate release; Pharmacokinetic; Retard capsule; Safety; Steady state; Tablet.

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Mean pharmacokinetic profiles. ER extended release, IR immediate release

References

    1. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4(8):1119–1129. doi: 10.1517/17425255.4.8.1119.
    1. Beeh KM, Beier J, Esperester A, et al. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008;13(12):557–562.
    1. Cazan D, Klimek L, Sperl A, et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018;17(12):1211–1224. doi: 10.1080/14740338.2018.1533954.
    1. European Medicines Agency (EMA) Ambroxol and bromhexine Article-31 referral—Pharmacovigilance Risk Assessment committee (PRAC) assessment report. 2015. . Accessed 2019.
    1. Sansom LN. Oral extended-release products. Aust Prescr. 1999;22(4):88–90. doi: 10.18773/austprescr.1999.072.
    1. Janssen TJ, Guelen PJ, Vree TB, et al. Bioavailability of ambroxol sustained release preparations. Part II: Single and multiple oral dose studies in man. Arzneimittelforschung. 1988;38(1):95–97.
    1. US Food and Drug Administration (FDA) Statistical approaches to establishing bioequivalence. 2001. . Accessed 2019.
    1. European Medicines Agency (EMA) Guideline on the investigation of bioequivalence. 2010. . Accessed 2019.
    1. Olivieri D, Zavattini G, Tomasini G, et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration. 1987;51(Suppl 1):42–51. doi: 10.1159/000195274.
    1. Cegla UH. Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients. Prax Klin Pneumol. 1988;42(9):715–721.
    1. Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial) Pulm Pharmacol Ther. 2004;17(1):27–34. doi: 10.1016/j.pupt.2003.08.004.
    1. Prevention of chronic bronchitis exacerbations with ambroxol (Mucosolvan retard). An open, long-term, multicenter study in 5635 patients. Respiration. 1989;55 Suppl 1:84–96.
    1. Kardos P, Beeh KM, Sent U, et al. Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. BMC Pharmacol Toxicol. 2018;19(1):40. doi: 10.1186/s40360-018-0229-y.
    1. Schmid J. Assay of ambroxol in biological fluids by capillary gas–liquid chromatography. J Chromatogr. 1987;414(1):65–75. doi: 10.1016/0378-4347(87)80025-7.
    1. Steinijans VW, Trautmann H, Johnson E, et al. Theophylline steady-state pharmacokinetics: recent concepts and their application in chronotherapy of reactive airway diseases. Chronobiol Int. 1987;4(3):331–347. doi: 10.3109/07420528709083523.
    1. Pfeffer M. Estimation of mean residence time from data obtained when multiple-dosing steady state has been reached. J Pharm Sci. 1984;73(6):854–856. doi: 10.1002/jps.2600730645.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren